2024年重点更新:脓毒症、急性呼吸窘迫综合征和社区获得性肺炎中糖皮质激素使用指南
该指南由22名多学科专家组成的小组制定,针对脓毒症、ARDS和CAP中糖皮质激素使用的5个PICO问题进行了系统评价,采用GRADE方法评估证据确定性并形成推荐。小组共发布4条推荐:对脓毒症休克患者和危重ARDS患者条件推荐使用糖皮质激素;对重症CAP住院患者强推荐使用;反对脓毒症休克使用大剂量短疗程糖皮质激素。关于ARDS中糖皮质激素种类、剂量和疗程的PICO问题,小组基于现有证据未能提供具体推荐。
要点
- 对脓毒症休克患者条件推荐使用糖皮质激素。
- 对危重ARDS患者条件推荐使用糖皮质激素。
- 对重症CAP住院患者强推荐使用糖皮质激素。
- 反对脓毒症休克使用大剂量/短疗程糖皮质激素。
- 基于现有证据,未能就ARDS中糖皮质激素的种类、剂量和疗程提供具体推荐。
适用人群与场景
- 住院成人及儿童脓毒症、ARDS和社区获得性肺炎患者。
处置流程与药物剂量
- 脓毒症休克患者:条件推荐使用糖皮质激素。
- 危重ARDS患者:条件推荐使用糖皮质激素。
- 重症CAP住院患者:强推荐使用糖皮质激素。
- 脓毒症休克患者:反对使用大剂量/短疗程糖皮质激素。
研究设计与关键结果
- 指南小组针对5个PICO问题,共发布4条推荐,涉及脓毒症、ARDS和CAP患者中糖皮质激素的使用。
- 推荐包括:对脓毒症休克患者和危重ARDS患者条件推荐使用糖皮质激素;对重症CAP住院患者强推荐使用;反对脓毒症休克使用大剂量/短疗程糖皮质激素。
- 关于ARDS中糖皮质激素种类、剂量和疗程的最终PICO问题,小组基于现有证据未能提供具体推荐。
证据类型、等级与局限
- 证据类型:指南(基于系统评价和GRADE方法)。
- 采用GRADE方法评估证据确定性,并使用证据到决策框架制定推荐。
- 推荐强度:条件推荐(脓毒症休克、危重ARDS)和强推荐(重症CAP)。
- 局限:基于现有证据,未能就ARDS中糖皮质激素的种类、剂量和疗程提供具体推荐。
对床旁实践的改变
- 对脓毒症休克患者,可考虑使用糖皮质激素(条件推荐)。
- 对危重ARDS患者,可考虑使用糖皮质激素(条件推荐)。
- 对重症CAP住院患者,推荐使用糖皮质激素(强推荐)。
- 对脓毒症休克患者,反对使用大剂量/短疗程糖皮质激素。
- 在ARDS中,糖皮质激素的种类、剂量和疗程尚无具体推荐,需根据临床情况个体化决策。
指南或共识出处
- 2024年重点更新:脓毒症、急性呼吸窘迫综合征和社区获得性肺炎中糖皮质激素使用指南(Crit Care Med)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: New evidence is available examining the use of corticosteroids in sepsis, acute respiratory distress syndrome (ARDS) and community-acquired pneumonia (CAP), warranting a focused update of the 2017 guideline on critical illness-related corticosteroid insufficiency.
OBJECTIVES: To develop evidence-based recommendations for use of corticosteroids in hospitalized adults and children with sepsis, ARDS, and CAP.
PANEL DESIGN: The 22-member panel included diverse representation from medicine, including adult and pediatric intensivists, pulmonologists, endocrinologists, nurses, pharmacists, and clinician-methodologists with expertise in developing evidence-based Clinical Practice Guidelines. We followed Society of Critical Care Medicine conflict of interest policies in all phases of the guideline development, including task force selection and voting.
METHODS: After development of five focused Population, Intervention, Control, and Outcomes (PICO) questions, we conducted systematic reviews to identify the best available evidence addressing each question. We evaluated the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach and formulated recommendations using the evidence-to-decision framework.
RESULTS: In response to the five PICOs, the panel issued four recommendations addressing the use of corticosteroids in patients with sepsis, ARDS, and CAP. These included a conditional recommendation to administer corticosteroids for patients with septic shock and critically ill patients with ARDS and a strong recommendation for use in hospitalized patients with severe CAP. The panel also recommended against high dose/short duration administration of corticosteroids for septic shock. In response to the final PICO regarding type of corticosteroid molecule in ARDS, the panel was unable to provide specific recommendations addressing corticosteroid molecule, dose, and duration of therapy, based on currently available evidence.
CONCLUSIONS: The panel provided updated recommendations based on current evidence to inform clinicians, patients, and other stakeholders on the use of corticosteroids for sepsis, ARDS, and CAP.
参考来源
- Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024. PMID: 38240492. doi:10.1097/CCM.0000000000006172
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。